Cargando…

Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space

INTRODUCTION: Carcinoma of unknown primary site is a heterogeneous group of cancer that is defined by the presence of metastatic disease with no identified primary tumor at initial presentation. Carcinoma of unknown primary site patients with unfavorable subsets particularly show poor prognosis with...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsukawa, Atsuki, Kato, Taigo, Kondo, Fuki, Kawasaki, Keisuke, Kawashima, Atsunari, Kiuchi, Hiroshi, Imamura, Ryoichi, Uemura, Motohide, Fukuhara, Shinichiro, Morii, Eiichi, Nonomura, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255281/
https://www.ncbi.nlm.nih.gov/pubmed/34258543
http://dx.doi.org/10.1002/iju5.12302
_version_ 1783717873754046464
author Matsukawa, Atsuki
Kato, Taigo
Kondo, Fuki
Kawasaki, Keisuke
Kawashima, Atsunari
Kiuchi, Hiroshi
Imamura, Ryoichi
Uemura, Motohide
Fukuhara, Shinichiro
Morii, Eiichi
Nonomura, Norio
author_facet Matsukawa, Atsuki
Kato, Taigo
Kondo, Fuki
Kawasaki, Keisuke
Kawashima, Atsunari
Kiuchi, Hiroshi
Imamura, Ryoichi
Uemura, Motohide
Fukuhara, Shinichiro
Morii, Eiichi
Nonomura, Norio
author_sort Matsukawa, Atsuki
collection PubMed
description INTRODUCTION: Carcinoma of unknown primary site is a heterogeneous group of cancer that is defined by the presence of metastatic disease with no identified primary tumor at initial presentation. Carcinoma of unknown primary site patients with unfavorable subsets particularly show poor prognosis with a median survival of 6–9 months with the treatment of empirical pactitaxel and carboplatin therapy (TC therapy). Recently, several studies have attempted to increase the response rate on the basis of prediction of the primary site by immunohistochemical tests or molecular profiling assays. CASE PRESENTATION: We report the case of a 77‐year‐old woman who presented with a mass on the left side of the abdominal aorta. Careful clinical and laboratory examinations could not identify the site of primary cancer. Pathologic examination of biopsied tissue revealed the tumor as undifferentiated carcinoma, which reached the diagnosis of carcinoma of unknown primary site with unfavorable subsets. She received empirical TC therapy and had prolonged survival of 26 months. After reviewing the pathological findings carefully, we noticed that Gross Cystic Disease Fluid Protein‐15 showed positive in the tumor, leading to the suspicion of breast cancer as the primary site. The specific therapy for breast cancer is similar to the empirical TC therapy in carcinoma of unknown primary site, which may contribute durable response in this patient. CONCLUSION: Site‐specific therapy based on careful immunohistochemical tests may improve the efficacy for carcinoma of unknown primary site patients with unfavorable prognosis subset.
format Online
Article
Text
id pubmed-8255281
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82552812021-07-12 Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space Matsukawa, Atsuki Kato, Taigo Kondo, Fuki Kawasaki, Keisuke Kawashima, Atsunari Kiuchi, Hiroshi Imamura, Ryoichi Uemura, Motohide Fukuhara, Shinichiro Morii, Eiichi Nonomura, Norio IJU Case Rep Case Reports INTRODUCTION: Carcinoma of unknown primary site is a heterogeneous group of cancer that is defined by the presence of metastatic disease with no identified primary tumor at initial presentation. Carcinoma of unknown primary site patients with unfavorable subsets particularly show poor prognosis with a median survival of 6–9 months with the treatment of empirical pactitaxel and carboplatin therapy (TC therapy). Recently, several studies have attempted to increase the response rate on the basis of prediction of the primary site by immunohistochemical tests or molecular profiling assays. CASE PRESENTATION: We report the case of a 77‐year‐old woman who presented with a mass on the left side of the abdominal aorta. Careful clinical and laboratory examinations could not identify the site of primary cancer. Pathologic examination of biopsied tissue revealed the tumor as undifferentiated carcinoma, which reached the diagnosis of carcinoma of unknown primary site with unfavorable subsets. She received empirical TC therapy and had prolonged survival of 26 months. After reviewing the pathological findings carefully, we noticed that Gross Cystic Disease Fluid Protein‐15 showed positive in the tumor, leading to the suspicion of breast cancer as the primary site. The specific therapy for breast cancer is similar to the empirical TC therapy in carcinoma of unknown primary site, which may contribute durable response in this patient. CONCLUSION: Site‐specific therapy based on careful immunohistochemical tests may improve the efficacy for carcinoma of unknown primary site patients with unfavorable prognosis subset. John Wiley and Sons Inc. 2021-05-27 /pmc/articles/PMC8255281/ /pubmed/34258543 http://dx.doi.org/10.1002/iju5.12302 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Matsukawa, Atsuki
Kato, Taigo
Kondo, Fuki
Kawasaki, Keisuke
Kawashima, Atsunari
Kiuchi, Hiroshi
Imamura, Ryoichi
Uemura, Motohide
Fukuhara, Shinichiro
Morii, Eiichi
Nonomura, Norio
Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space
title Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space
title_full Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space
title_fullStr Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space
title_full_unstemmed Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space
title_short Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space
title_sort durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255281/
https://www.ncbi.nlm.nih.gov/pubmed/34258543
http://dx.doi.org/10.1002/iju5.12302
work_keys_str_mv AT matsukawaatsuki durableresponseofchemotherapyforcancerofunknownprimarywithunfavorablesubsetdevelopedinretroperitonealspace
AT katotaigo durableresponseofchemotherapyforcancerofunknownprimarywithunfavorablesubsetdevelopedinretroperitonealspace
AT kondofuki durableresponseofchemotherapyforcancerofunknownprimarywithunfavorablesubsetdevelopedinretroperitonealspace
AT kawasakikeisuke durableresponseofchemotherapyforcancerofunknownprimarywithunfavorablesubsetdevelopedinretroperitonealspace
AT kawashimaatsunari durableresponseofchemotherapyforcancerofunknownprimarywithunfavorablesubsetdevelopedinretroperitonealspace
AT kiuchihiroshi durableresponseofchemotherapyforcancerofunknownprimarywithunfavorablesubsetdevelopedinretroperitonealspace
AT imamuraryoichi durableresponseofchemotherapyforcancerofunknownprimarywithunfavorablesubsetdevelopedinretroperitonealspace
AT uemuramotohide durableresponseofchemotherapyforcancerofunknownprimarywithunfavorablesubsetdevelopedinretroperitonealspace
AT fukuharashinichiro durableresponseofchemotherapyforcancerofunknownprimarywithunfavorablesubsetdevelopedinretroperitonealspace
AT moriieiichi durableresponseofchemotherapyforcancerofunknownprimarywithunfavorablesubsetdevelopedinretroperitonealspace
AT nonomuranorio durableresponseofchemotherapyforcancerofunknownprimarywithunfavorablesubsetdevelopedinretroperitonealspace